Zydus FDA Monday, September 12, 2022 0.00 Neutral

FDA Approves LENALIDOMIDE — Zydus Pharmaceuticals USA Inc.

Zydus Pharmaceuticals USA Inc. announced on Tuesday the FDA approval of a generic version of global immunomodulatory drug manufacturer Johnson & Johnson's oral drug Lenalidomide, a strong signal of intensified price competition for the hematologic oncology franchise following the upcoming expiration of blockbuster patents.

View original filing at SEC.gov →
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.

Get real-time financial news in your trading bot or app

GET FREE KEY — 10,000 calls/day